133 related articles for article (PubMed ID: 36007725)
21. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy.
Schraag A; Klumpp B; Afat S; Gatidis S; Nikolaou K; Eigentler TK; Othman AE
Eur J Radiol; 2019 Dec; 121():108688. PubMed ID: 31704599
[TBL] [Abstract][Full Text] [Related]
22. Sentinel node tumor burden in prediction of prognosis in melanoma patients.
Palve J; Ylitalo L; Luukkaala T; Jernman J; Korhonen N
Clin Exp Metastasis; 2020 Apr; 37(2):365-376. PubMed ID: 32076905
[TBL] [Abstract][Full Text] [Related]
23. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications.
Lavine SD; Petrovich Z; Cohen-Gadol AA; Masri LS; Morton DL; O'Day SJ; Essner R; Zelman V; Yu C; Luxton G; Apuzzo ML
Neurosurgery; 1999 Jan; 44(1):59-64; discussion 64-6. PubMed ID: 9894964
[TBL] [Abstract][Full Text] [Related]
24. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Moretto R; Rossini D; Zucchelli G; Lonardi S; Bergamo F; Santini D; Cupini S; Tomasello G; Caponnetto S; Zaniboni A; Antoniotti C; Pietrantonio F; Buonadonna A; Marmorino F; Bordonaro R; Fea E; Tamburini E; Boccaccino A; Grande R; Aprile G; Falcone A; Cremolini C
Eur J Cancer; 2020 Nov; 139():81-89. PubMed ID: 32979645
[TBL] [Abstract][Full Text] [Related]
25. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):849-855. PubMed ID: 36302495
[TBL] [Abstract][Full Text] [Related]
26. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
27. Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres.
Bhooshan N; Sharma NK; Badiyan S; Kaiser A; Moeslein FM; Kwok Y; Amin PP; Kudryasheva S; Chuong MD
J Gastrointest Oncol; 2016 Dec; 7(6):931-937. PubMed ID: 28078116
[TBL] [Abstract][Full Text] [Related]
28. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
29. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
30. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
[TBL] [Abstract][Full Text] [Related]
31. Clinical correlates and prognostic value of different metastatic sites in patients with malignant melanoma of the skin: a SEER database analysis.
Abdel-Rahman O
J Dermatolog Treat; 2018 Mar; 29(2):176-181. PubMed ID: 28745581
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors of liver metastases from uveal melanoma.
Kodjikian L; Grange JD; Baldo S; Baillif S; Garweg JG; Rivoire M
Graefes Arch Clin Exp Ophthalmol; 2005 Oct; 243(10):985-93. PubMed ID: 15891893
[TBL] [Abstract][Full Text] [Related]
33. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma.
Powell JW; Chung CT; Shah HR; Canute GW; Hodge CJ; Bassano DA; Liu L; Mitchell L; Hahn SS
J Neurosurg; 2008 Dec; 109 Suppl():122-8. PubMed ID: 19123898
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
36. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
Basler L; Gabryś HS; Hogan SA; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner MW; Dummer R; Guckenberger M; Levesque MP
Clin Cancer Res; 2020 Aug; 26(16):4414-4425. PubMed ID: 32253232
[TBL] [Abstract][Full Text] [Related]
37. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort.
Hompland I; Bruland ØS; Hølmebakk T; Poulsen JP; Stoldt S; Hall KS; Boye K
Acta Oncol; 2017 Oct; 56(10):1317-1323. PubMed ID: 28557540
[TBL] [Abstract][Full Text] [Related]
38. Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease.
Cao Y; Chen H; Sahgal A; Erler D; Badellino S; Biswas T; Dagan R; Foote MC; Louie AV; Poon I; Ricardi U; Redmond KJ
Cancer Med; 2021 Nov; 10(22):8091-8099. PubMed ID: 34668651
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.
Kroese TE; Jorritsma NKN; van Laarhoven HWM; Verhoeven RHA; Mook S; Haj Mohammad N; Ruurda JP; van Rossum PSN; van Hillegersberg R
Clin Transl Radiat Oncol; 2022 Nov; 37():109-115. PubMed ID: 36186924
[TBL] [Abstract][Full Text] [Related]
40. Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with Stereotactic Radiotherapy.
Franzese C; Navarria P; Bellu L; Marzo MA; Clerici E; Badalamenti M; Baldaccini D; Franceschini D; Comito T; Teriaca A; D'agostino G; Reggiori G; Tomatis S; Scorsetti M
Clin Oncol (R Coll Radiol); 2022 Jun; 34(6):379-385. PubMed ID: 35027286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
